Key result
Continuous 72-hour infusion of Adriamycin via a central venous catheter resulted in more hospital admissions for treatment-related complications compared to intravenous bolus (15.4% vs 0%; P=0.03).
Why the study?
Does continuous 72 hour infusion of doxorubicin via a right atrial catheter increase hospital admissions for treatment-related complications compared to intravenous bolus in patients with high grade soft tissue sarcoma?
RCT (n=47)
Does continuous 72 hour infusion of doxorubicin via a right atrial catheter increase hospital admissions for treatment-related complications compared to intravenous bolus in patients with high grade soft tissue sarcoma?
Absolute Event Rate: 15.4% vs 0%
p-value: p=0.03
Continuous 72-hour infusion of doxorubicin via a central venous catheter significantly increases the risk of hospital admissions for catheter-related complications compared to intravenous bolus in sarcoma patients.
Continuous infusion may increase hospitalizations; leaves open optimal Adriamycin scheduling in randomized trials.
As part of a prospective randomized study in patients with high grade soft tissue sarcoma (STS), 47 patients received post-operative adjuvant Adriamycin. The method of administration was randomized to intravenous bolus (B) or to continuous 72 hour infusion (CI) via a Silastic right atrial catheter. Both groups received 60 mg/m2 every 3 weeks. There were nine hospital admissions for treatment related complications in four of the 26 CI patients compared to none in the 21 B patients (P = 0.03). All of the admissions related to complications involving the central venous catheter (CVC). This apparent increased risk for hospital admission secondary to treatment related complications in patients treated with CI must be considered in the planning of future therapeutic trials.
No takes yet. Share an insight, caveat, or question.
Israel et al. (1990) conducted an RCT in High grade soft tissue sarcoma (STS) (n=47). Continuous 72 hour infusion (CI) of Adriamycin via a Silastic right atrial catheter vs. Intravenous bolus (B) of Adriamycin was evaluated on Hospital admissions for treatment related complications (p=0.03). Continuous 72-hour infusion of Adriamycin via a central venous catheter resulted in more hospital admissions for treatment-related complications compared to intravenous bolus (15.4% vs 0%; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: